Marine-derived protein kinase inhibitors for neuroinflammatory diseases

Ning, Chong; Wang, Hui‐Min David; Gao, Rong; Chang, Yu‐Chia; Hu, Fengqing; Meng, Xianjun; Huang, Sheng-Lung

doi:10.1186/s12938-018-0477-5

Cited by 30 publications

(18 citation statements)

References 91 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ellagic acid [214] Entacapone (Comtan, ASI-6) [12,215,216] Enzastaurin [164] Epicatechin [128,160,193,194] Epigallocatechin-3-gallate [117,217,218] Etidronate (HEDPA) [219] Exifone [12] F13714 [220] F15599 [220,221] Farrerol [222] Fisetin (3,3 ,4 ,7-Tetrahydroxy flavone) [223][224][225] Fraxetin [117] Galangin [226] Gallic acid and derivatives [214,227,228] Gallocatechin [128] Garcinol [229] Genistein [117,128,230,231] Glutamine [232] Glutathione derivatives [63] Glutathione -hydroxyquinoline compound [233] Glutathione-l-DOPA compound [234] Gly-N-C-DOPA [209] GSK2795039 [108] Guanabenz [235] Hesperidin [128,236] Hinokitiol […”

Section: Compound Name(s) Referencesmentioning

confidence: 99%

“…Imipramine [247] Isobavachalcone [248] Isochlorogenic acid [167] Isoquercetin (Isoquercitrin) [249] Kaempferol [128,160,193,194] Kaempferol, 3-O-a-l arabinofuranoside-7-O-a-l-rhamnopyranoside [214] KR33493 [250] Kukoamine [251] Lestaurtinib [164] Lipoic acid [252][253][254] Luteolin [128] LY354740 [115] M10 [24] M30 (VAR10303) [112,255] M99 [24] Macranthoin G [256] Magnesium lithospermate B [257] [160,193,194,267] [18F]MPPF [107] MSX-3 [268] Myricetin [128,269,270] Myricitrin [271] Naringenin [128,272] Naringin [117,273,274] Nicotinamide adenine dinucleotide phosphate (NADPH) [275,276] Nicotinamide mononucleotide [277] Nitecapone [278] Nordihydroguaiaretic [160,193,194] Oleuropein…”

Section: Compound Name(s) Referencesmentioning

confidence: 99%

See 1 more Smart Citation

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Tosato

Marco

2019

Biomolecules

View full text Add to dashboard Cite

The present review reports a list of approximately 800 compounds which have been used, tested or proposed for Parkinson’s disease (PD) therapy in the year range 2014–2019 (April): name(s), chemical structure and references are given. Among these compounds, approximately 250 have possible or established metal-chelating properties towards Cu(II), Cu(I), Fe(III), Fe(II), Mn(II), and Zn(II), which are considered to be involved in metal dyshomeostasis during PD. Speciation information regarding the complexes formed by these ions and the 250 compounds has been collected or, if not experimentally available, has been estimated from similar molecules. Stoichiometries and stability constants of the complexes have been reported; values of the cologarithm of the concentration of free metal ion at equilibrium (pM), and of the dissociation constant Kd (both computed at pH = 7.4 and at total metal and ligand concentrations of 10–6 and 10–5 mol/L, respectively), charge and stoichiometry of the most abundant metal–ligand complexes existing at physiological conditions, have been obtained. A rigorous definition of the reported amounts is given, the possible usefulness of this data is described, and the need to characterize the metal–ligand speciation of PD drugs is underlined.

show abstract

Section: Compound Name(s) Referencesmentioning

confidence: 99%

Section: Compound Name(s) Referencesmentioning

confidence: 99%

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Tosato

Marco

2019

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Several studies reported neuroprotective role of astaxanthin and fucoxanthin [145, [282][283][284][285][286][287], Sargassum spp. [288][289][290][291][292][293][294][295], Saccorhiza polyschide [283], Codium tomentosum [296], Ulva spp [256,267,293,[297][298][299][300], Ecklonia maxima [256,[301][302][303], Gracilaria spp. (Figure 12) [296,[304][305][306][307][308][309][310][311], Gelidium pristoides [312,313], Halimeda incrassate [314,315], Bryothamniom triquetrum [316][317][318], Chondrus crispus ( Figure 13) [319,320], Hypnea valentiae (…”

Section: Neuroprotection In Stroke Alzheimer's and Parkinsonismmentioning

confidence: 99%

Seaweeds: An Extensive Review of Medicinal Values

Mohiuddin¹

2019

APCT

View full text Add to dashboard Cite

The global economic impact of the five leading chronic diseases-cancer, diabetes, mental illness, CVD, and respiratory disease-could reach $47 trillion over the next 20 years, according to a study by the World Economic Forum (WEF). According to the WHO, 80% of the world's population primarily those of developing countries rely on plant-derived medicines for the healthcare. The purported efficacies of seaweed derived phytochemicals showing great potential in obesity, T2DM, metabolic syndrome, CVD, IBD, sexual dysfunction and some cancers. Therefore, WHO, UN-FAO, UNICEF and governments have shown a growing interest in this unconventional food with health-promoting effects. Edible marine macro-algae (seaweed) are of interest because of their value in nutrition and medicine. Seaweeds contain several bioactive substances like polysaccharides, proteins, lipids, polyphenols, and pigments, all of which may have beneficial health properties. People consume seaweed as food in various forms: raw as salad and vegetable, pickle with sauce or with vinegar, relish or sweetened jellies and also cooked for vegetable soup. By cultivating seaweed, coastal people are getting an alternative livelihood as well as advancing their lives. In 2005, world seaweed production was totaled 14.7 million tons which more than double (30.4 million tons) in 2015. The present market value is nearly $6.5 billion and projected to reach some $9 billion seaweed global market by 2024. Aquaculture is recognized as the most sustainable means of seaweed production and accounts for approximately 27.3 million tons (more than 90%) of global seaweed production per annum. Asian countries produced 80% for world markets where China alone produces half of the total demand. The top six seaweed producing countries are China,

show abstract

“…Drug activities and drug mechanisms of action are investigated on cellular and/or in mouse model systems. Every marine bioactive compound is studied in a single disease (COPD or MCI/AD) model [ 66 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 ].…”

Section: Mild Cognitive Impairmentmentioning

confidence: 99%

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

et al. 2018

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is characterized by long-term airflow limitation. Early-onset COPD in non-smoker subjects is ≥60 years and in the elderly is often associated with different comorbidities. Cognitive impairment is one of the most common feature in patients with COPD, and is associated with COPD severity and comorbidities. Cognitive impairment in COPD enhances the assistance requirement in different aspects of daily living, treatment adherence, and effectual self-management.This review describes various bioactive compounds of natural marine sources that modulate different targets shared by both COPD and cognitive impairment and hypothesizes a possible link between these two syndromes.

show abstract

Marine-derived protein kinase inhibitors for neuroinflammatory diseases

Cited by 30 publications

References 91 publications

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

Seaweeds: An Extensive Review of Medicinal Values

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

Contact Info

Product

Resources

About